Johnson & Johnson (NYSE:JNJ) has been on a roll. Thanks to a steady string of successful new drug launches, the company has beat analysts' earnings estimates in each of the past four quarters.
When Johnson reports earnings on July 15, investors will learn whether fast growth continued for key drugs including Zytiga, Xarelto, and Olysio.
In the following slideshow, you'll see what has been driving Johnson's success this past year and what you should be looking for in Johnson's release.
Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.